FIXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FIXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Homology Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.36. Homology Medicines's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-05-12), Homology Medicines's share price is $0.9347. Homology Medicines's Median PS Value is $0.00. Therefore, Homology Medicines's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Homology Medicines's Median PS Value or its related term are showing as below:
The historical data trend for Homology Medicines's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Homology Medicines Annual Data | |||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
Homology Medicines Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Homology Medicines's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Homology Medicines's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Homology Medicines's Price-to-Median-PS-Value falls into.
Homology Medicines's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0.36 | * | 0 | |
= | 0.00 |
10-Year Median PS Ratio is 0.
Homology Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Homology Medicines (NAS:FIXX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Homology Medicines's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 0.9347 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Homology Medicines's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Alloway | officer: See Remarks | C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730 |
Albert Seymour | officer: Chief Scientific Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Julie Jordan | officer: Chief Medical Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Michael Lee Blum | officer: Chief Commercial Officer | C/O HOMOLOGY MEDICINES, INC., 45 WIGGINS AVENUE, BEDFORD MA 01730 |
W Bradford Smith | officer: CFO, Treasurer & Secretary | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Arthur Tzianabos | director, officer: President & CEO | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Timothy P Kelly | officer: See Remarks | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Gabriel Cohn | officer: Chief Medical Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Kush Parmar | director, 10 percent owner | C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
5am Ventures Iv, L.p. | 10 percent owner | 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Jeffrey V. Poulton | director | 300 THIRD STREET, CAMBRIDGE MA 02142 |
James E Flynn | director, 10 percent owner, other: *Director by Deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Alise Reicin | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Siyamak Rasty | officer: Chief Operating Officer | C/O HOMOLOGY MEDICINES, INC., ONE PATRIOTS PARK, BEDFORD MA 01730 |
Vida Ventures, Llc | 10 percent owner | 40 BROAD STREET, SUITE 201, BOSTON MA 02109 |
From GuruFocus
By PRNewswire • 11-21-2023
By sperokesalga sperokesalga • 03-02-2023
By Marketwired • 07-27-2023
By PRNewswire PRNewswire • 07-15-2022
By sperokesalga sperokesalga • 05-03-2023
By Stock market mentor Stock market mentor • 01-04-2023
By Business Wire • 11-16-2023
By PRNewswire • 08-16-2023
By Marketwired • 08-14-2023
By PurpleRose PurpleRose • 08-11-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.